Blueprint Medicines Corporation (BPMC): Price and Financial Metrics


Blueprint Medicines Corporation (BPMC): $45.23

0.34 (+0.76%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BPMC to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

BPMC POWR Grades

  • Growth is the dimension where BPMC ranks best; there it ranks ahead of 78.19% of US stocks.
  • BPMC's strongest trending metric is Quality; it's been moving up over the last 178 days.
  • BPMC ranks lowest in Stability; there it ranks in the 4th percentile.

BPMC Stock Summary

  • Of note is the ratio of BLUEPRINT MEDICINES CORP's sales and general administrative expense to its total operating expenses; only 10.36% of US stocks have a lower such ratio.
  • With a year-over-year growth in debt of 190.9%, BLUEPRINT MEDICINES CORP's debt growth rate surpasses 92.69% of about US stocks.
  • As for revenue growth, note that BPMC's revenue has grown 154.07% over the past 12 months; that beats the revenue growth of 94.53% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to BLUEPRINT MEDICINES CORP are HOWL, SIMO, IDYA, RXDX, and TNGX.
  • BPMC's SEC filings can be seen here. And to visit BLUEPRINT MEDICINES CORP's official web site, go to www.blueprintmedicines.com.

BPMC Valuation Summary

  • BPMC's EV/EBIT ratio is -3.7; this is 143.02% lower than that of the median Healthcare stock.
  • BPMC's price/sales ratio has moved NA NA over the prior 92 months.

Below are key valuation metrics over time for BPMC.

Stock Date P/S P/B P/E EV/EBIT
BPMC 2022-11-25 9.9 4.2 -3.7 -3.7
BPMC 2022-11-23 9.9 4.2 -3.7 -3.7
BPMC 2022-11-22 9.6 4.1 -3.6 -3.6
BPMC 2022-11-21 9.5 4.0 -3.6 -3.6
BPMC 2022-11-18 9.3 4.0 -3.5 -3.5
BPMC 2022-11-17 9.4 4.0 -3.5 -3.5

BPMC Growth Metrics

    Its 5 year price growth rate is now at 62.77%.
  • Its 4 year net income to common stockholders growth rate is now at -412.09%.
  • The 2 year net cashflow from operations growth rate now stands at 0.51%.
Over the past 33 months, BPMC's revenue has gone up $205,764,000.

The table below shows BPMC's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 272.276 -394.986 -717.557
2022-06-30 230.487 -360.692 -701.635
2022-03-31 221.235 -305.601 -650.37
2021-12-31 180.08 -298.653 -644.085
2021-09-30 107.165 -309.338 -411.067
2021-06-30 828.095 408.584 340.152

BPMC's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • BPMC has a Quality Grade of C, ranking ahead of 33.2% of graded US stocks.
  • BPMC's asset turnover comes in at 0.067 -- ranking 297th of 682 Pharmaceutical Products stocks.
  • OTLC, SGEN, and OCGN are the stocks whose asset turnover ratios are most correlated with BPMC.

The table below shows BPMC's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.067 0.871 -0.440
2021-06-30 0.512 0.992 0.352
2021-03-31 0.566 0.999 0.382
2020-12-31 0.634 0.999 0.411
2020-09-30 0.812 1.000 0.485
2020-06-30 0.095 0.998 -0.729

BPMC Price Target

For more insight on analysts targets of BPMC, see our BPMC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $119.69 Average Broker Recommendation 1.47 (Moderate Buy)

BPMC Stock Price Chart Interactive Chart >

Price chart for BPMC

BPMC Price/Volume Stats

Current price $45.23 52-week high $111.78
Prev. close $44.89 52-week low $40.78
Day low $44.41 Volume 614,600
Day high $45.81 Avg. volume 765,410
50-day MA $52.82 Dividend yield N/A
200-day MA $59.48 Market Cap 2.71B

Blueprint Medicines Corporation (BPMC) Company Bio


Blueprint Medicines Corporation makes kinase drugs to treat patients with genomically defined diseases. The company was founded in 2008 and is based in Cambridge, Massachusetts.


BPMC Latest News Stream


Event/Time News Detail
Loading, please wait...

BPMC Latest Social Stream


Loading social stream, please wait...

View Full BPMC Social Stream

Latest BPMC News From Around the Web

Below are the latest news stories about BLUEPRINT MEDICINES CORP that investors may wish to consider to help them evaluate BPMC as an investment opportunity.

Blueprint Medicines (BPMC) Files Ayvakit sNDA for Indolent SM

Blueprint Medicines (BPMC) submits a supplemental new drug application for its lead drug, Ayvakit, for the treatment of indolent systemic mastocytosis to the FDA.

Yahoo | November 23, 2022

Blueprint Medicines Submits Supplemental New Drug Application to FDA for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis

Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the submission of a supplemental new drug application to the U.S. Food and Drug Administration (FDA) for AYVAKIT® (avapritinib) for the treatment of adults with indolent systemic mastocytosis (SM). AYVAKIT was designed to potently and selectively inhibit D816V mutant KIT, the underlying cause of SM in about 95 percent of cases.

Yahoo | November 22, 2022

Ken Fisher Super Stocks: 10 Biggest Small-Cap Stocks

In this article, we discuss the 10 biggest small-cap stocks in the Ken Fisher portfolio. If you want to see more stocks in this selection, check out Ken Fisher Super Stocks: 5 Biggest Small-Cap Stocks. US stocks have been beaten down by inflation recently. Jim Paulsen, chief investment strategist at The Leuthold Group, noted that […]

Yahoo | November 17, 2022

Blueprint Medicines to Present at Upcoming Investor Conferences

Blueprint Medicines Corporation (Nasdaq: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced its participation the following upcoming investor conferences:

Yahoo | November 9, 2022

Blueprint Medicines Third Quarter 2022 Earnings: Beats Expectations

Blueprint Medicines ( NASDAQ:BPMC ) Third Quarter 2022 Results Key Financial Results Revenue: US$66.0m (up 173% from 3Q...

Yahoo | November 8, 2022

Read More 'BPMC' Stories Here

BPMC Price Returns

1-mo -14.72%
3-mo -38.23%
6-mo -20.26%
1-year -53.98%
3-year -44.87%
5-year -39.74%
YTD -57.77%
2021 -4.49%
2020 40.00%
2019 48.60%
2018 -28.51%
2017 168.84%

Continue Researching BPMC

Want to see what other sources are saying about Blueprint Medicines Corp's financials and stock price? Try the links below:

Blueprint Medicines Corp (BPMC) Stock Price | Nasdaq
Blueprint Medicines Corp (BPMC) Stock Quote, History and News - Yahoo Finance
Blueprint Medicines Corp (BPMC) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7225 seconds.